Severe central nervous system fungal infection case report

6 evidence topics · 1 source

Objective

Reported infection

“We report a case of severe Aspergillus encephalitis following tirabrutinib administration.” (opens the source at this quote in a new tab)

Location and study date

No evidence found.

Study design

Eligibility criteria

Not applicable.

Treatment

Study outcomes

Rationale for using fungal infection as an observed safety outcome

Not applicable.

Statistical analysis description

Number of participants (Planned and analyzed)

Description of analysis sets

Not applicable.

Results

Participant disposition

Fatal outcome

“Subsequently, a fatal subcortical hemorrhage occurred.” (opens the source at this quote in a new tab)

Baseline characteristics

Age and sex

“A man in his 50s” (opens the source at this quote in a new tab)

Efficacy results

Initial tumor response

“The tumor shrank dramatically, and improvement in neurological symptoms was observed.” (opens the source at this quote in a new tab)

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

Treatment interruption and hepatic toxicity

“liver dysfunction” (opens the source at this quote in a new tab)
“tirabrutinib was discontinued.” (opens the source at this quote in a new tab)

Study limitations

Summary

The report describes one participant with Aspergillus encephalitis after tirabrutinib exposure and a subsequent fatal subcortical hemorrhage. A case report can identify a possible safety signal but cannot determine incidence or establish that tirabrutinib alone caused the infection or hemorrhage.